Resource utilization and cost of influenza requiring hospitalization in Canadian adults: A study from the serious outcomes surveillance network of the Canadian Immunization Research Network

the Serious Outcomes Surveillance Network of the Canadian Immunization Research Network (CIRN) Investigators; The Toronto Invasive Bacterial Diseases Network (TIBDN) Investigators

doi:10.1111/irv.12521

Resource utilization and cost of influenza requiring hospitalization in Canadian adults: A study from the serious outcomes surveillance network of the Canadian Immunization Research Network

the Serious Outcomes Surveillance Network of the Canadian Immunization Research Network (CIRN) Investigators, The Toronto Invasive Bacterial Diseases Network (TIBDN) Investigators

Medicine

Medicine

Producción científica: Contribución a una revista › Artículo › revisión exhaustiva

30 Citas (Scopus)

Resumen

Background: Consideration of cost determinants is crucial to inform delivery of public vaccination programs. Objectives: To estimate the average total cost of laboratory-confirmed influenza requiring hospitalization in Canadians prior to, during, and 30 days following discharge. To analyze effects of patient/disease characteristics, treatment, and regional differences in costs. Methods: Study utilized previously recorded clinical characteristics, resource use, and outcomes of laboratory-confirmed influenza patients admitted to hospitals in the Serious Outcomes Surveillance (SOS), Canadian Immunization Research Network (CIRN), from 2010/11 to 2012/13. Unit costs including hospital overheads were linked to inpatient/outpatient resource utilization before and after admissions. Results: Dataset included 2943 adult admissions to 17 SOS Network hospitals and 24 Toronto Invasive Bacterial Disease Network hospitals. Mean age was 69.5 years. Average hospital stay was 10.8 days (95% CI: 10.3, 11.3), general ward stays were 9.4 days (95% CI: 9.0, 9.8), and ICU stays were 9.8 days (95% CI: 8.6, 11.1) for the 14% of patients admitted to the ICU. Average cost per case was $14 612 CAD (95% CI: $13 852, $15 372) including $133 (95% CI: $116, $150) for medical care prior to admission, $14 031 (95% CI: $13 295, $14 768) during initial hospital stay, $447 (95% CI: $271, $624) post-discharge, including readmission within 30 days. Conclusion: The cost of laboratory-confirmed influenza was higher than previous estimates, driven mostly by length of stay and analyzing only laboratory-confirmed influenza cases. The true per-patient cost of influenza-related hospitalization has been underestimated, and prevention programs should be evaluated in this context.

Idioma original	English
Páginas (desde-hasta)	232-240
Número de páginas	9
Publicación	Influenza and other Respiratory Viruses
Volumen	12
N.º	2
DOI	https://doi.org/10.1111/irv.12521
Estado	Published - mar. 2018

Nota bibliográfica

Funding Information:
All authors participated in the design or implementation or analysis, interpretation of the study, and the development of this manuscript. All authors had full access to the data and gave final approval before submission. Carita Ng and Margaret Hux report payments to ICON plc from the GSK group of companies for the conduct of the study. Stephen Noorduyn and Edward Thommes report they were employed by the GSK group of companies during the conduct of the study. Melissa K Andrew reports grants from the GSK group of companies, Pfizer, and Sanofi, but no personal payments. Janet McElhaney reports payments from PCIRN for the conduct of the study, and payments to her institution from the GSK group of companies and Sanofi for her participation in advisory boards. Andre Poirier reports payments from Actelion, Sanofi-Pasteur, and Genentech. Jeff Powis reports payments from the GSK group of companies, Merck, Roche, and Synthetic Biologics, outside the submitted work. Rohita Sharma is employed by the GSK group of companies and hold shares in the GSK group of companies. Louis Valiquette reports payments to her institution from the GSK group of companies for the conduct of the study. Grant Stiver reports receiving funding from the GSK group of companies for PCIRN research through the University of British Columbia. Todd Hatchette and Shelly A McNeil report payments to their institution from the GSK group of companies for the conduct of the study, and payments from Pfizer, Merck, Novartis, and Sanofi-Pasteur, outside the submitted work. The following authors have nothing to disclose: May ElSherif, Lingyun Ye, Ron Goeree, Ardith Ambrose, Guy Boivin, William Bowie, Karen Green, Jennie Johnstone, Kevin Katz, Jason Leblanc, Mark Loeb, Donna MacKinnon-Cameron, Anne McCarthy, Allison McGeer, David Richardson, Makeda Semret, Stephanie Smith, Daniel Smyth, Sylvie Trottier, and Duncan Webster.

Funding Information:
This work is funded by the Canadian Immunization Research Network and GlaxoSmithKline (Canada).

Publisher Copyright:
© 2017 The Authors. Influenza and Other Respiratory Viruses Published by John Wiley & Sons Ltd.

ASJC Scopus Subject Areas

Epidemiology
Pulmonary and Respiratory Medicine
Public Health, Environmental and Occupational Health
Infectious Diseases

ODS de las Naciones Unidas

Este resultado contribuye a los siguientes Objetivos de Desarrollo Sostenible

Acceder al documento

10.1111/irv.12521

Otros archivos y enlaces

Citar esto

the Serious Outcomes Surveillance Network of the Canadian Immunization Research Network (CIRN) Investigators, & The Toronto Invasive Bacterial Diseases Network (TIBDN) Investigators (2018). Resource utilization and cost of influenza requiring hospitalization in Canadian adults: A study from the serious outcomes surveillance network of the Canadian Immunization Research Network. Influenza and other Respiratory Viruses, 12(2), 232-240. https://doi.org/10.1111/irv.12521

Resource utilization and cost of influenza requiring hospitalization in Canadian adults: A study from the serious outcomes surveillance network of the Canadian Immunization Research Network. / the Serious Outcomes Surveillance Network of the Canadian Immunization Research Network (CIRN) Investigators; The Toronto Invasive Bacterial Diseases Network (TIBDN) Investigators.
En: Influenza and other Respiratory Viruses, Vol. 12, N.º 2, 03.2018, p. 232-240.

Producción científica: Contribución a una revista › Artículo › revisión exhaustiva

the Serious Outcomes Surveillance Network of the Canadian Immunization Research Network (CIRN) Investigators & The Toronto Invasive Bacterial Diseases Network (TIBDN) Investigators 2018, 'Resource utilization and cost of influenza requiring hospitalization in Canadian adults: A study from the serious outcomes surveillance network of the Canadian Immunization Research Network', Influenza and other Respiratory Viruses, vol. 12, n.º 2, pp. 232-240. https://doi.org/10.1111/irv.12521

the Serious Outcomes Surveillance Network of the Canadian Immunization Research Network (CIRN) Investigators, The Toronto Invasive Bacterial Diseases Network (TIBDN) Investigators. Resource utilization and cost of influenza requiring hospitalization in Canadian adults: A study from the serious outcomes surveillance network of the Canadian Immunization Research Network. Influenza and other Respiratory Viruses. 2018 mar.;12(2):232-240. doi: 10.1111/irv.12521

the Serious Outcomes Surveillance Network of the Canadian Immunization Research Network (CIRN) Investigators ; The Toronto Invasive Bacterial Diseases Network (TIBDN) Investigators. / Resource utilization and cost of influenza requiring hospitalization in Canadian adults : A study from the serious outcomes surveillance network of the Canadian Immunization Research Network. En: Influenza and other Respiratory Viruses. 2018 ; Vol. 12, N.º 2. pp. 232-240.

@article{26e5269adb4e4862976865e949e1820e,

title = "Resource utilization and cost of influenza requiring hospitalization in Canadian adults: A study from the serious outcomes surveillance network of the Canadian Immunization Research Network",

abstract = "Background: Consideration of cost determinants is crucial to inform delivery of public vaccination programs. Objectives: To estimate the average total cost of laboratory-confirmed influenza requiring hospitalization in Canadians prior to, during, and 30 days following discharge. To analyze effects of patient/disease characteristics, treatment, and regional differences in costs. Methods: Study utilized previously recorded clinical characteristics, resource use, and outcomes of laboratory-confirmed influenza patients admitted to hospitals in the Serious Outcomes Surveillance (SOS), Canadian Immunization Research Network (CIRN), from 2010/11 to 2012/13. Unit costs including hospital overheads were linked to inpatient/outpatient resource utilization before and after admissions. Results: Dataset included 2943 adult admissions to 17 SOS Network hospitals and 24 Toronto Invasive Bacterial Disease Network hospitals. Mean age was 69.5 years. Average hospital stay was 10.8 days (95% CI: 10.3, 11.3), general ward stays were 9.4 days (95% CI: 9.0, 9.8), and ICU stays were 9.8 days (95% CI: 8.6, 11.1) for the 14% of patients admitted to the ICU. Average cost per case was $14 612 CAD (95% CI: $13 852, $15 372) including $133 (95% CI: $116, $150) for medical care prior to admission, $14 031 (95% CI: $13 295, $14 768) during initial hospital stay, $447 (95% CI: $271, $624) post-discharge, including readmission within 30 days. Conclusion: The cost of laboratory-confirmed influenza was higher than previous estimates, driven mostly by length of stay and analyzing only laboratory-confirmed influenza cases. The true per-patient cost of influenza-related hospitalization has been underestimated, and prevention programs should be evaluated in this context.",

author = "{the Serious Outcomes Surveillance Network of the Canadian Immunization Research Network (CIRN) Investigators} and {The Toronto Invasive Bacterial Diseases Network (TIBDN) Investigators} and Carita Ng and Lingyun Ye and Noorduyn, {Stephen G.} and Margaret Hux and Edward Thommes and Ron Goeree and Ardith Ambrose and Andrew, {Melissa K.} and Todd Hatchette and Guy Boivin and William Bowie and May ElSherif and Karen Green and Jennie Johnstone and Kevin Katz and Jason Leblanc and Mark Loeb and Donna MacKinnon-Cameron and Anne McCarthy and Janet McElhaney and Allison McGeer and Andre Poirier and Jeff Powis and David Richardson and Rohita Sharma and Makeda Semret and Stephanie Smith and Daniel Smyth and Grant Stiver and Sylvie Trottier and Louis Valiquette and Duncan Webster and McNeil, {Shelly A.}",

note = "Funding Information: All authors participated in the design or implementation or analysis, interpretation of the study, and the development of this manuscript. All authors had full access to the data and gave final approval before submission. Carita Ng and Margaret Hux report payments to ICON plc from the GSK group of companies for the conduct of the study. Stephen Noorduyn and Edward Thommes report they were employed by the GSK group of companies during the conduct of the study. Melissa K Andrew reports grants from the GSK group of companies, Pfizer, and Sanofi, but no personal payments. Janet McElhaney reports payments from PCIRN for the conduct of the study, and payments to her institution from the GSK group of companies and Sanofi for her participation in advisory boards. Andre Poirier reports payments from Actelion, Sanofi-Pasteur, and Genentech. Jeff Powis reports payments from the GSK group of companies, Merck, Roche, and Synthetic Biologics, outside the submitted work. Rohita Sharma is employed by the GSK group of companies and hold shares in the GSK group of companies. Louis Valiquette reports payments to her institution from the GSK group of companies for the conduct of the study. Grant Stiver reports receiving funding from the GSK group of companies for PCIRN research through the University of British Columbia. Todd Hatchette and Shelly A McNeil report payments to their institution from the GSK group of companies for the conduct of the study, and payments from Pfizer, Merck, Novartis, and Sanofi-Pasteur, outside the submitted work. The following authors have nothing to disclose: May ElSherif, Lingyun Ye, Ron Goeree, Ardith Ambrose, Guy Boivin, William Bowie, Karen Green, Jennie Johnstone, Kevin Katz, Jason Leblanc, Mark Loeb, Donna MacKinnon-Cameron, Anne McCarthy, Allison McGeer, David Richardson, Makeda Semret, Stephanie Smith, Daniel Smyth, Sylvie Trottier, and Duncan Webster. Funding Information: This work is funded by the Canadian Immunization Research Network and GlaxoSmithKline (Canada). Publisher Copyright: {\textcopyright} 2017 The Authors. Influenza and Other Respiratory Viruses Published by John Wiley & Sons Ltd.",

year = "2018",

month = mar,

doi = "10.1111/irv.12521",

language = "English",

volume = "12",

pages = "232--240",

journal = "Influenza and other Respiratory Viruses",

issn = "1750-2640",

publisher = "Wiley-Blackwell",

number = "2",

}

TY - JOUR

T1 - Resource utilization and cost of influenza requiring hospitalization in Canadian adults

T2 - A study from the serious outcomes surveillance network of the Canadian Immunization Research Network

AU - the Serious Outcomes Surveillance Network of the Canadian Immunization Research Network (CIRN) Investigators

AU - The Toronto Invasive Bacterial Diseases Network (TIBDN) Investigators

AU - Ng, Carita

AU - Ye, Lingyun

AU - Noorduyn, Stephen G.

AU - Hux, Margaret

AU - Thommes, Edward

AU - Goeree, Ron

AU - Ambrose, Ardith

AU - Andrew, Melissa K.

AU - Hatchette, Todd

AU - Boivin, Guy

AU - Bowie, William

AU - ElSherif, May

AU - Green, Karen

AU - Johnstone, Jennie

AU - Katz, Kevin

AU - Leblanc, Jason

AU - Loeb, Mark

AU - MacKinnon-Cameron, Donna

AU - McCarthy, Anne

AU - McElhaney, Janet

AU - McGeer, Allison

AU - Poirier, Andre

AU - Powis, Jeff

AU - Richardson, David

AU - Sharma, Rohita

AU - Semret, Makeda

AU - Smith, Stephanie

AU - Smyth, Daniel

AU - Stiver, Grant

AU - Trottier, Sylvie

AU - Valiquette, Louis

AU - Webster, Duncan

AU - McNeil, Shelly A.

N1 - Funding Information: All authors participated in the design or implementation or analysis, interpretation of the study, and the development of this manuscript. All authors had full access to the data and gave final approval before submission. Carita Ng and Margaret Hux report payments to ICON plc from the GSK group of companies for the conduct of the study. Stephen Noorduyn and Edward Thommes report they were employed by the GSK group of companies during the conduct of the study. Melissa K Andrew reports grants from the GSK group of companies, Pfizer, and Sanofi, but no personal payments. Janet McElhaney reports payments from PCIRN for the conduct of the study, and payments to her institution from the GSK group of companies and Sanofi for her participation in advisory boards. Andre Poirier reports payments from Actelion, Sanofi-Pasteur, and Genentech. Jeff Powis reports payments from the GSK group of companies, Merck, Roche, and Synthetic Biologics, outside the submitted work. Rohita Sharma is employed by the GSK group of companies and hold shares in the GSK group of companies. Louis Valiquette reports payments to her institution from the GSK group of companies for the conduct of the study. Grant Stiver reports receiving funding from the GSK group of companies for PCIRN research through the University of British Columbia. Todd Hatchette and Shelly A McNeil report payments to their institution from the GSK group of companies for the conduct of the study, and payments from Pfizer, Merck, Novartis, and Sanofi-Pasteur, outside the submitted work. The following authors have nothing to disclose: May ElSherif, Lingyun Ye, Ron Goeree, Ardith Ambrose, Guy Boivin, William Bowie, Karen Green, Jennie Johnstone, Kevin Katz, Jason Leblanc, Mark Loeb, Donna MacKinnon-Cameron, Anne McCarthy, Allison McGeer, David Richardson, Makeda Semret, Stephanie Smith, Daniel Smyth, Sylvie Trottier, and Duncan Webster. Funding Information: This work is funded by the Canadian Immunization Research Network and GlaxoSmithKline (Canada). Publisher Copyright: © 2017 The Authors. Influenza and Other Respiratory Viruses Published by John Wiley & Sons Ltd.

PY - 2018/3

Y1 - 2018/3

N2 - Background: Consideration of cost determinants is crucial to inform delivery of public vaccination programs. Objectives: To estimate the average total cost of laboratory-confirmed influenza requiring hospitalization in Canadians prior to, during, and 30 days following discharge. To analyze effects of patient/disease characteristics, treatment, and regional differences in costs. Methods: Study utilized previously recorded clinical characteristics, resource use, and outcomes of laboratory-confirmed influenza patients admitted to hospitals in the Serious Outcomes Surveillance (SOS), Canadian Immunization Research Network (CIRN), from 2010/11 to 2012/13. Unit costs including hospital overheads were linked to inpatient/outpatient resource utilization before and after admissions. Results: Dataset included 2943 adult admissions to 17 SOS Network hospitals and 24 Toronto Invasive Bacterial Disease Network hospitals. Mean age was 69.5 years. Average hospital stay was 10.8 days (95% CI: 10.3, 11.3), general ward stays were 9.4 days (95% CI: 9.0, 9.8), and ICU stays were 9.8 days (95% CI: 8.6, 11.1) for the 14% of patients admitted to the ICU. Average cost per case was $14 612 CAD (95% CI: $13 852, $15 372) including $133 (95% CI: $116, $150) for medical care prior to admission, $14 031 (95% CI: $13 295, $14 768) during initial hospital stay, $447 (95% CI: $271, $624) post-discharge, including readmission within 30 days. Conclusion: The cost of laboratory-confirmed influenza was higher than previous estimates, driven mostly by length of stay and analyzing only laboratory-confirmed influenza cases. The true per-patient cost of influenza-related hospitalization has been underestimated, and prevention programs should be evaluated in this context.

AB - Background: Consideration of cost determinants is crucial to inform delivery of public vaccination programs. Objectives: To estimate the average total cost of laboratory-confirmed influenza requiring hospitalization in Canadians prior to, during, and 30 days following discharge. To analyze effects of patient/disease characteristics, treatment, and regional differences in costs. Methods: Study utilized previously recorded clinical characteristics, resource use, and outcomes of laboratory-confirmed influenza patients admitted to hospitals in the Serious Outcomes Surveillance (SOS), Canadian Immunization Research Network (CIRN), from 2010/11 to 2012/13. Unit costs including hospital overheads were linked to inpatient/outpatient resource utilization before and after admissions. Results: Dataset included 2943 adult admissions to 17 SOS Network hospitals and 24 Toronto Invasive Bacterial Disease Network hospitals. Mean age was 69.5 years. Average hospital stay was 10.8 days (95% CI: 10.3, 11.3), general ward stays were 9.4 days (95% CI: 9.0, 9.8), and ICU stays were 9.8 days (95% CI: 8.6, 11.1) for the 14% of patients admitted to the ICU. Average cost per case was $14 612 CAD (95% CI: $13 852, $15 372) including $133 (95% CI: $116, $150) for medical care prior to admission, $14 031 (95% CI: $13 295, $14 768) during initial hospital stay, $447 (95% CI: $271, $624) post-discharge, including readmission within 30 days. Conclusion: The cost of laboratory-confirmed influenza was higher than previous estimates, driven mostly by length of stay and analyzing only laboratory-confirmed influenza cases. The true per-patient cost of influenza-related hospitalization has been underestimated, and prevention programs should be evaluated in this context.

UR - http://www.scopus.com/inward/record.url?scp=85040867330&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85040867330&partnerID=8YFLogxK

U2 - 10.1111/irv.12521

DO - 10.1111/irv.12521

M3 - Article

C2 - 29125689

AN - SCOPUS:85040867330

SN - 1750-2640

VL - 12

SP - 232

EP - 240

JO - Influenza and other Respiratory Viruses

JF - Influenza and other Respiratory Viruses

IS - 2

ER -

Resource utilization and cost of influenza requiring hospitalization in Canadian adults: A study from the serious outcomes surveillance network of the Canadian Immunization Research Network

Resumen

Nota bibliográfica

ASJC Scopus Subject Areas

ODS de las Naciones Unidas

Acceder al documento

Otros archivos y enlaces

Huella

Citar esto